Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-340

ROFL. The clown has pounced on unclecousin Cletus' seat as the music stopped.

I unignored out of curiosity. But after the below I'll stick to circuses for competent clowns who get paid for honest work.

IMHO, what you are doing probably works on many internet forums, but is unlikely effective in the IMU forum. But whatevs.

What you have said is incorrect almost in its entirety regarding stats, and it is also out of context.
See below a screenshot covering two important points:
1. The OS of 0.418 for the Her-vaxx trial interim data was STATISTICALLY SIGNIFICANT.
2. The IDMC (who, unlike lily livered clowns, are experts) advised reducing the trial numbers, due to the strong evidence of Her-vaxx survival effect.

The KM curve is a gold standard measure in cancer trials. The interim her-vaxx was pretty amazing due to the early and clear separation of the two curves.



Stick to playing your hot cousins banjo.